Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

NCT05360238 is registered in ClinicalTrials.gov with Mustang Bio as lead sponsor.

NCT NCT05360238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05360238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Lead sponsor
Mustang Bio
Phase
Phase 1/2
Overall status
Terminated
Start date
May 24, 2022
Completion date
April 12, 2024
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma refractory, chronic lymphoid leukemia in relapse, follicular b-cell non-hodgkin's lymphoma, mantle cell lymphoma recurrent, mantle cell lymphoma refractory, small lymphocytic lymphoma, relapsed, waldenstrom's macroglobulinemia recurrent, waldenstrom's macroglobulinemia refractory